---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-078581"
form_type: "8-K"
ticker: "CERT"
cik: "0001827090"
company_name: "Certara, Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:38:50.244834+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance

## Summary
- Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.
- Transaction expected to close in H2 2024, subject to regulatory approval and customary conditions.
- Chemaxon expected to generate >$20M software revenue in 2024; adjusted EBITDA margin near Certara's corporate average by end 2025.
- Certara reiterates 2024 revenue, adjusted EBITDA margin (31-33%), and adjusted diluted EPS guidance from May 7 earnings call.
- Acquisition expands Certara's drug discovery biosimulation portfolio; long-term partnership with Chemaxon.

## SEC filing metadata
- accession: 0001104659-24-078581
- form_type: 8-K
- ticker: CERT
- cik: 0001827090
- company_name: Certara, Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827090/000110465924078581/0001104659-24-078581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827090/000110465924078581/tm2418257d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-078581
- JSON: https://secwatch.observer/filing/0001104659-24-078581.json
- Plain text: https://secwatch.observer/filing/0001104659-24-078581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.